BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FRA: NPAU) CEO Dr. Ahmad Doroudian, discusses a range of topics as the company looks forward to a productive 2022. BetterLife is currently in the preclinical stage of research into its non-psychoactive derivative of LSD as a treatment for depression and cluster headaches. The company is also conducting clinical trials for inhalable interferon as a treatment for COVID-19.